PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1566002
PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1566002
United States In-Vitro Diagnostics Market, By Product and Services; By Technique; By Application; By End User, Trend Analysis, Competitive Landscape & Forecast, 2019-2030
United States In-Vitro Diagnostics (IVD) Market Size Expands at CAGR of 5.7% to Surpass USD 49 Billion by 2030
United States In-Vitro Diagnostics (IVD) Market is flourishing because of the increasing prevalence of chronic diseases and innovations in IVD technology, such as point-of-care testing, molecular diagnostics, and automation.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated United States In-Vitro Diagnostics (IVD) Market size at USD 33.50 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects United States In-Vitro Diagnostics (IVD) Market size to expand at a CAGR of 5.70% reaching a value of USD 49.10 billion by 2030. The growing elderly population and the increasing incidence of both communicable and non-communicable diseases are key drivers of United States in-vitro diagnostics (IVD) market. The number of point-of-care tests is also rising along with the use of automation in labs and automated equipment, which is expected to provide United States in-vitro diagnostics (IVD) market enormous potential for expansion over the period in analysis.
Opportunity - Rising adoption of automation in IVD labs
The increasing adoption of automated instruments and automation in laboratories is anticipated to present lucrative growth opportunities for United States In-Vitro Diagnostics (IVD) Market. Automated instruments provide several benefits, such as higher performance levels, enhanced productivity, data accuracy, and meeting safety protocols. As a result, many industry players are developing and launching automated instruments that offer higher efficiency and effectiveness in diagnostic tests. The increasing test volumes and shortage of skilled lab personnel are anticipated to boost automation in laboratories, thus, in turn, driving the growth of United States In-Vitro Diagnostics (IVD) Market.
Hospitals Are Leading End Users of IVD in United States Market
The increasing number of hospital facilities and dependence on IVD for diagnosis and treatment decisions fuel the demand for in-vitro diagnostic tests. The high rate of in-patient and out-patient treatment in hospitals due to the presence of advanced diagnostic setups further contributes to its market growth. Hence, the hospital segment dominates United States In-Vitro Diagnostics (IVD) Market by end user. Meanwhile, the point-of-care (PoC) segment is also expected to grow at a high rate over the forecast period. Other major end user segments in United States In-Vitro Diagnostics (IVD) Market include standalone laboratories, and academic & medical schools.
Impact of Escalating Geopolitical Tensions on United States In-Vitro Diagnostics (IVD) Market
The escalating geopolitical tensions disrupt the growth of United States In-Vitro Diagnostics (IVD) Market. For example, China is one of the United States' top economic partners and a significant exporter of medical diagnostic test equipment. However, the growing hostility between the two nations driven by China's developing military might pose a risk to the healthcare industry. Additionally, geopolitical conflicts affect supply chains, making healthcare supplies harder to get and ultimately leading to price increases that might affect the growth of United States Market for In-Vitro Diagnostics (IVD).
Competitive Landscape
United States In-Vitro Diagnostics (IVD) market is intensely competitive, as a number of companies are competing to gain a significant market share. Key players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Johnson & Johnson, Ortho-Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, bioMerieux, QIAGEN, and Becton, Dickinson and Company.
To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and United States In-Vitro Diagnostics (IVD) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in United States In-Vitro Diagnostics (IVD) Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
2. Executive Summary
3. United States In-Vitro Diagnostics (IVD) Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Increasing Prevalence of Chronic Diseases
- 3.2.1.2. Innovations in IVD Technology, such as Point-Of-Care Testing, Molecular Diagnostics, and Automation
- 3.2.1.3. Rising Healthcare Expenditure
- 3.2.1.4. Growing Awareness about Early Disease Detection
- 3.2.2. Restraints
- 3.2.2.1. Unfavorable Reimbursement Scenario
- 3.2.2.2. High Cost of Development
- 3.2.2.3. Stringent Regulatory Environment
- 3.2.3. Opportunities
- 3.2.3.1. Emerging Technologies such as Liquid Biopsy, Digital Pathology, and Microfluidics
- 3.2.3.2. Increasing Adoption of Personalized Medicine
- 3.2.3.3. Growing Demand for Rapid and Accessible Diagnostic Solutions
- 3.2.4. Challenges
- 3.2.4.1. Shortage of Skilled Professionals in the IVD Industry
- 3.2.4.2. Increasing Concerns about Data Privacy and Security
- 3.2.1. Growth Drivers
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
4. United States In-Vitro Diagnostics (IVD) Market: Marketing Strategies
5. United States In-Vitro Diagnostics (IVD) Market: Pricing Analysis
6. United States In-Vitro Diagnostics (IVD) Market Overview
- 6.1. Market Size & Forecast, 2019-2030
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share & Forecast
- 6.2.1. By Product and Services
- 6.2.1.1. Reagents & Kits
- 6.2.1.2. Instruments
- 6.2.1.3. Software & Services
- 6.2.2. By Technique
- 6.2.2.1. Molecular Diagnostics
- 6.2.2.2. Tissue Diagnostics
- 6.2.2.3. Clinical Chemistry
- 6.2.2.4. Immunodiagnostics
- 6.2.2.5. Hematology
- 6.2.2.6. Others
- 6.2.3. By Application
- 6.2.3.1. Infectious Diseases
- 6.2.3.2. Cancer
- 6.2.3.3. Cardiac Diseases
- 6.2.3.4. Immune System Disorders
- 6.2.3.5. Nephrological Diseases
- 6.2.3.6. Gastrointestinal Diseases
- 6.2.3.7. Others
- 6.2.4. By End User
- 6.2.4.1. Standalone Laboratories
- 6.2.4.2. Hospitals
- 6.2.4.3. Academic and Medical Schools
- 6.2.4.4. Point of Care
- 6.2.4.5. Others
- 6.2.1. By Product and Services
7. Competitive Landscape
- 7.1. List of Key Players and Their Products
- 7.2. United States In-Vitro Diagnostics (IVD) Company Market Share Analysis, 2023
- 7.3. Competitive Benchmarking, By Operating Parameters
- 7.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
8. Impact of Escalating Geopolitical Tensions on United States In-Vitro Diagnostics (IVD) Market
9. Company Profiles (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook, and SWOT Analysis)
- 9.1. Roche Diagnostics
- 9.2. Abbott Laboratories
- 9.3. Siemens Healthineers
- 9.4. Danaher Corporation
- 9.5. Thermo Fisher Scientific
- 9.6. Johnson & Johnson
- 9.7. Ortho-Clinical Diagnostics
- 9.8. Sysmex Corporation
- 9.9. Bio-Rad Laboratories
- 9.10. bioMerieux
- 9.11. QIAGEN
- 9.12. Becton, Dickinson and Company
- 9.13. Other prominent players
10. Key Strategic Recommendations
11. Research Methodology
- 11.1. Qualitative Research
- 11.1.1. Primary & Secondary Research
- 11.2. Quantitative Research
- 11.3. Market Breakdown & Data Triangulation
- 11.3.1. Secondary Research
- 11.3.2. Primary Research
- 11.4. Breakdown of Primary Research Respondents
- 11.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.
List of Figures
- Figure 1 United States In-Vitro Diagnostics (IVD) Segmentation
- Figure 2 United States In-Vitro Diagnostics (IVD) Market Value Chain Analysis
- Figure 3 Company Market Share Analysis, 2023
- Figure 4 United States In-Vitro Diagnostics (IVD) Market Size, By Value (USD Billion), 2019-2030
- Figure 5 United States In-Vitro Diagnostics (IVD) Market Share, By Product and Services, By Value (USD Billion), 2019-2030
- Figure 6 United States In-Vitro Diagnostics (IVD) Market Share, By Technique, By Value (USD Billion), 2019-2030
- Figure 7 United States In-Vitro Diagnostics (IVD) Market Share, By Application, By Value (USD Billion), 2019-2030
- Figure 8 United States In-Vitro Diagnostics (IVD) Market Share, By End User, By Value (USD Billion), 2019-2030
List of Tables
- Table 1 United States In-Vitro Diagnostics (IVD) Market Size, By Value (USD Billion), 2019-2030
- Table 2 United States In-Vitro Diagnostics (IVD) Market Share, By Product and Services, By Value (USD Billion), 2019-2030
- Table 3 United States In-Vitro Diagnostics (IVD) Market Share, By Technique, By Value (USD Billion), 2019-2030
- Table 4 United States In-Vitro Diagnostics (IVD) Market Share, By Application, By Value (USD Billion), 2019-2030
- Table 5 United States In-Vitro Diagnostics (IVD) Market Share, By End User, By Value (USD Billion), 2019-2030
- Table 6 Roche Diagnostics Company Overview
- Table 7 Roche Diagnostics Financial Overview
- Table 8 Abbott Laboratories Company Overview
- Table 9 Abbott Laboratories Financial Overview
- Table 10 Siemens Healthineers Company Overview
- Table 11 Siemens Healthineers Financial Overview
- Table 12 Danaher Corporation Company Overview
- Table 13 Danaher Corporation Financial Overview
- Table 14 Thermo Fisher Scientific Company Overview
- Table 15 Thermo Fisher Scientific Financial Overview
- Table 16 Johnson & Johnson Company Overview
- Table 17 Johnson & Johnson Financial Overview
- Table 18 Ortho-Clinical Diagnostics Company Overview
- Table 19 Ortho-Clinical Diagnostics Financial Overview
- Table 20 Sysmex Corporation Company Overview
- Table 21 Sysmex Corporation Financial Overview
- Table 22 Bio-Rad Laboratories Company Overview
- Table 23 Bio-Rad Laboratories Financial Overview
- Table 24 bioMerieux Company Overview
- Table 25 bioMerieux Financial Overview
- Table 26 QIAGEN Company Overview
- Table 27 QIAGEN Financial Overview
- Table 28 Becton, Dickinson and Company - Company Overview
- Table 29 Becton, Dickinson and Company Financial Overview
